Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 20682796)

1.

Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma.

Albesiano E, Davis M, See AP, Han JE, Lim M, Pardoll DM, Kim Y.

Cancer Res. 2010 Aug 15;70(16):6467-76. doi: 10.1158/0008-5472.CAN-09-4058. Epub 2010 Aug 3.

2.

Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.

Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR.

Oncogene. 2015 May 18. doi: 10.1038/onc.2015.171. [Epub ahead of print]

PMID:
25982282
3.

Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer.

Mali SB.

Oral Oncol. 2015 Jun;51(6):565-569. doi: 10.1016/j.oraloncology.2015.03.004. Epub 2015 Mar 25. Review.

PMID:
25817923
4.

The role of STAT3 in tumor-mediated immune suppression.

Ferguson SD, Srinivasan VM, Heimberger AB.

J Neurooncol. 2015 Feb 22. [Epub ahead of print]

PMID:
25700834
5.

14-3-3ζ regulates immune response through Stat3 signaling in oral squamous cell carcinoma.

Han X, Han Y, Jiao H, Jie Y.

Version 2. Mol Cells. 2015 Feb 28 [revised 2015 Mar 10];38(2):112-21. doi: 10.14348/molcells.2015.2101. Epub 2014 Dec 30.

6.

Stat3 is activated in skin lesions by the local application of imiquimod, a ligand of TLR7, and inhibited by the recombinant peptide aptamer rS3-PA.

Mack L, Brill B, Delis N, Borghouts C, Weber A, Groner B.

Horm Mol Biol Clin Investig. 2012 Jun;10(2):265-72. doi: 10.1515/hmbci-2012-0007.

PMID:
25436683
7.

Molecular pathways: IL11 as a tumor-promoting cytokine-translational implications for cancers.

Ernst M, Putoczki TL.

Clin Cancer Res. 2014 Nov 15;20(22):5579-88. doi: 10.1158/1078-0432.CCR-13-2492. Epub 2014 Jul 29.

PMID:
25074610
8.

Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model.

Cao Y, Zhou X, Zhou M, Xu D, Ma Q, Zhang P, Huang X, Li Q, Ma D, Zhou J.

Cancer Biol Ther. 2014 Sep;15(9):1153-62. doi: 10.4161/cbt.29453. Epub 2014 Jun 10.

PMID:
24915165
9.

Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.

Farren MR, Carlson LM, Netherby CS, Lindner I, Li PK, Gabrilovich DI, Abrams SI, Lee KP.

Sci Signal. 2014 Feb 18;7(313):ra16. doi: 10.1126/scisignal.2004656.

10.

STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma.

Klein JD, Sano D, Sen M, Myers JN, Grandis JR, Kim S.

PLoS One. 2014 Jan 3;9(1):e81819. doi: 10.1371/journal.pone.0081819. eCollection 2014.

11.

Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Gildener-Leapman N, Ferris RL, Bauman JE.

Oral Oncol. 2013 Dec;49(12):1089-96. doi: 10.1016/j.oraloncology.2013.09.009. Epub 2013 Oct 11. Review.

PMID:
24126223
12.

STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas.

Timme S, Ihde S, Fichter CD, Waehle V, Bogatyreva L, Atanasov K, Kohler I, Schöpflin A, Geddert H, Faller G, Klimstra D, Tang L, Reinheckel T, Hauschke D, Busch H, Boerries M, Werner M, Lassmann S.

Oncogene. 2014 Jun 19;33(25):3256-66. doi: 10.1038/onc.2013.298. Epub 2013 Aug 5.

PMID:
23912451
13.

Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy.

Emeagi PU, Maenhout S, Dang N, Heirman C, Thielemans K, Breckpot K.

Gene Ther. 2013 Nov;20(11):1085-92. doi: 10.1038/gt.2013.35. Epub 2013 Jun 27.

PMID:
23804077
14.

Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma.

Li F, Shanmugam MK, Chen L, Chatterjee S, Basha J, Kumar AP, Kundu TK, Sethi G.

Cancer Prev Res (Phila). 2013 Aug;6(8):843-54. doi: 10.1158/1940-6207.CAPR-13-0070. Epub 2013 Jun 26.

15.

Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.

Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC.

Am J Respir Cell Mol Biol. 2013 Aug;49(2):241-50. doi: 10.1165/rcmb.2012-0244OC.

PMID:
23526220
16.

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.

Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, Blosser RL, Tam AJ, Bruno T, Zhang H, Pardoll D, Kim Y.

J Clin Invest. 2013 Apr;123(4):1580-9.

17.

A synergistic interaction between transcription factors nuclear factor-κB and signal transducers and activators of transcription 3 promotes gastric cancer cell migration and invasion.

Yoon J, Cho SJ, Ko YS, Park J, Shin DH, Hwang IC, Han SY, Nam SY, Kim MA, Chang MS, Lee HS, Kim WH, Lee BL.

BMC Gastroenterol. 2013 Feb 12;13:29. doi: 10.1186/1471-230X-13-29.

18.

Cell-line-specific stimulation of tumor cell aggressiveness by wound healing factors - a central role for STAT3.

Ekblad L, Lindgren G, Persson E, Kjellén E, Wennerberg J.

BMC Cancer. 2013 Jan 25;13:33. doi: 10.1186/1471-2407-13-33.

19.

Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1.

Gupta SC, Phromnoi K, Aggarwal BB.

Biochem Pharmacol. 2013 Apr 1;85(7):898-912. doi: 10.1016/j.bcp.2012.12.018. Epub 2012 Dec 29.

PMID:
23279849
20.

Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity.

Kulesza DW, Carré T, Chouaib S, Kaminska B.

Exp Cell Res. 2013 Feb 15;319(4):506-16. doi: 10.1016/j.yexcr.2012.11.005. Epub 2012 Nov 10.

PMID:
23149124
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk